NASDAQ:VCEL

Vericel Competitors

$57.65
-0.33 (-0.57 %)
(As of 04/16/2021 11:03 AM ET)
Add
Compare
Today's Range
$57.32
Now: $57.65
$58.60
50-Day Range
$40.41
MA: $50.94
$59.82
52-Week Range
$10.74
Now: $57.65
$60.49
Volume2,235 shs
Average Volume910,870 shs
Market Capitalization$2.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.11

Competitors

Vericel (NASDAQ:VCEL) Vs. NBIX, CRSP, FATE, XLRN, TWST, and DNLI

Should you be buying VCEL stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Vericel, including Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Twist Bioscience (TWST), and Denali Therapeutics (DNLI).

Neurocrine Biosciences (NASDAQ:NBIX) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Valuation & Earnings

This table compares Neurocrine Biosciences and Vericel's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million11.43$37.01 million$0.39244.23
Vericel$117.85 million22.55$-9,660,000.00$0.18320.28

Neurocrine Biosciences has higher revenue and earnings than Vericel. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Neurocrine Biosciences and Vericel, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences081202.60
Vericel02602.75

Neurocrine Biosciences currently has a consensus price target of $128.7222, suggesting a potential upside of 35.14%. Vericel has a consensus price target of $49.00, suggesting a potential downside of 15.00%. Given Neurocrine Biosciences' higher probable upside, equities analysts clearly believe Neurocrine Biosciences is more favorable than Vericel.

Profitability

This table compares Neurocrine Biosciences and Vericel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
Vericel0.12%0.13%0.10%

Volatility & Risk

Neurocrine Biosciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500.

Institutional and Insider Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 93.1% of Vericel shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 4.3% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Vericel on 10 of the 13 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares Vericel and CRISPR Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$117.85 million22.55$-9,660,000.00$0.18320.28
CRISPR Therapeutics$289.59 million30.88$66.86 million$1.17101.33

CRISPR Therapeutics has higher revenue and earnings than Vericel. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vericel has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.

Insider and Institutional Ownership

93.1% of Vericel shares are held by institutional investors. Comparatively, 66.4% of CRISPR Therapeutics shares are held by institutional investors. 4.3% of Vericel shares are held by insiders. Comparatively, 17.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Vericel and CRISPR Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vericel0.12%0.13%0.10%
CRISPR Therapeutics-273.10%-20.72%-18.35%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Vericel and CRISPR Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vericel02602.75
CRISPR Therapeutics241202.56

Vericel presently has a consensus target price of $49.00, indicating a potential downside of 15.00%. CRISPR Therapeutics has a consensus target price of $158.80, indicating a potential upside of 35.14%. Given CRISPR Therapeutics' higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Vericel.

Summary

CRISPR Therapeutics beats Vericel on 8 of the 14 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Fate Therapeutics (NASDAQ:FATE) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Profitability

This table compares Vericel and Fate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vericel0.12%0.13%0.10%
Fate Therapeutics-810.13%-35.51%-25.40%

Institutional and Insider Ownership

93.1% of Vericel shares are held by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are held by institutional investors. 4.3% of Vericel shares are held by company insiders. Comparatively, 21.4% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Vericel and Fate Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vericel02602.75
Fate Therapeutics04902.69

Vericel presently has a consensus target price of $49.00, suggesting a potential downside of 15.00%. Fate Therapeutics has a consensus target price of $108.3125, suggesting a potential upside of 32.15%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Vericel.

Risk & Volatility

Vericel has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500.

Valuation & Earnings

This table compares Vericel and Fate Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$117.85 million22.55$-9,660,000.00$0.18320.28
Fate Therapeutics$10.68 million719.71$-98,150,000.00($1.44)-56.92

Vericel has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Acceleron Pharma (NASDAQ:XLRN) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.

Risk and Volatility

Vericel has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500. Comparatively, Acceleron Pharma has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Institutional and Insider Ownership

93.1% of Vericel shares are held by institutional investors. Comparatively, 79.8% of Acceleron Pharma shares are held by institutional investors. 4.3% of Vericel shares are held by insiders. Comparatively, 2.5% of Acceleron Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Vericel and Acceleron Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$117.85 million22.55$-9,660,000.00$0.18320.28
Acceleron Pharma$73.99 million101.50$-124,860,000.00($2.38)-52.11

Vericel has higher revenue and earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vericel and Acceleron Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vericel0.12%0.13%0.10%
Acceleron Pharma-157.84%-31.62%-28.11%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Vericel and Acceleron Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vericel02602.75
Acceleron Pharma031012.86

Vericel presently has a consensus price target of $49.00, suggesting a potential downside of 15.00%. Acceleron Pharma has a consensus price target of $148.2143, suggesting a potential upside of 19.50%. Given Acceleron Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Acceleron Pharma is more favorable than Vericel.

Summary

Vericel beats Acceleron Pharma on 9 of the 15 factors compared between the two stocks.

Twist Bioscience (NASDAQ:TWST) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Risk and Volatility

Twist Bioscience has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, meaning that its share price is 211% more volatile than the S&P 500.

Institutional and Insider Ownership

87.9% of Twist Bioscience shares are owned by institutional investors. Comparatively, 93.1% of Vericel shares are owned by institutional investors. 7.0% of Twist Bioscience shares are owned by insiders. Comparatively, 4.3% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Twist Bioscience and Vericel, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Twist Bioscience11302.40
Vericel02602.75

Twist Bioscience presently has a consensus price target of $137.50, suggesting a potential downside of 0.56%. Vericel has a consensus price target of $49.00, suggesting a potential downside of 15.00%. Given Twist Bioscience's higher possible upside, analysts clearly believe Twist Bioscience is more favorable than Vericel.

Profitability

This table compares Twist Bioscience and Vericel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Twist Bioscience-155.31%-44.62%-35.49%
Vericel0.12%0.13%0.10%

Earnings & Valuation

This table compares Twist Bioscience and Vericel's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Twist Bioscience$90.10 million74.66$-139,930,000.00($3.00)-46.09
Vericel$117.85 million22.55$-9,660,000.00$0.18320.28

Vericel has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Twist Bioscience on 10 of the 14 factors compared between the two stocks.

Denali Therapeutics (NASDAQ:DNLI) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Earnings & Valuation

This table compares Denali Therapeutics and Vericel's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$26.68 million246.41$-197,610,000.00($2.07)-26.25
Vericel$117.85 million22.55$-9,660,000.00$0.18320.28

Vericel has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Denali Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500.

Profitability

This table compares Denali Therapeutics and Vericel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Denali Therapeutics-968.59%-39.19%-30.71%
Vericel0.12%0.13%0.10%

Institutional & Insider Ownership

68.2% of Denali Therapeutics shares are held by institutional investors. Comparatively, 93.1% of Vericel shares are held by institutional investors. 19.3% of Denali Therapeutics shares are held by company insiders. Comparatively, 4.3% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Denali Therapeutics and Vericel, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Denali Therapeutics01702.88
Vericel02602.75

Denali Therapeutics currently has a consensus price target of $75.8571, indicating a potential upside of 39.60%. Vericel has a consensus price target of $49.00, indicating a potential downside of 15.00%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Denali Therapeutics is more favorable than Vericel.

Summary

Vericel beats Denali Therapeutics on 8 of the 14 factors compared between the two stocks.


Vericel Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.25-0.3%$8.98 billion$788.10 million102.42Analyst Upgrade
Increase in Short Interest
Analyst Revision
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$118.56-4.5%$8.94 billion$289.59 million-36.37
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$81.96-3.0%$7.92 billion$10.68 million-44.54
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$124.03-1.3%$7.51 billion$73.99 million-47.89
Twist Bioscience logo
TWST
Twist Bioscience
1.2$138.28-2.7%$6.91 billion$90.10 million-36.87Insider Selling
Analyst Revision
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$54.34-3.1%$6.78 billion$26.68 million-24.59
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.22-0.0%$6.62 billion$195.99 million288.88Insider Selling
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$41.85-2.8%$5.99 billion$85.07 million-44.05
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$113.57-1.9%$5.92 billionN/A-48.95
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$45.92-1.9%$5.76 billion$8.09 million-19.46Analyst Downgrade
Insider Selling
News Coverage
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.26-0.2%$4.65 billion$503.70 million33.03
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.44-1.3%$4.62 billionN/A-15.23
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$73.18-0.8%$4.61 billion$20,000.00-5.21
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.14-1.0%$4.43 billionN/A-15.70Analyst Report
Increase in Short Interest
Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$71.44-3.0%$3.60 billionN/A-41.06Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$71.87-3.2%$3.31 billion$125.57 million-42.03Insider Selling
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.39-4.1%$3.05 billionN/A0.00News Coverage
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$40.32-3.1%$2.96 billion$50.04 million0.00
Editas Medicine logo
EDIT
Editas Medicine
1.6$35.35-15.9%$2.76 billion$20.53 million-20.32Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.36-1.1%$2.09 billion$31.43 million-5.04Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.94-2.7%$2.00 billion$44.67 million-2.64
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.85-0.8%$1.95 billionN/A-11.14Decrease in Short Interest
Gap Up
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.50-0.2%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$76.36-0.3%$1.70 billionN/A-51.59
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.39-3.3%$1.69 billion$102.43 million-18.98
Immunovant logo
IMVT
Immunovant
1.8$15.58-1.9%$1.56 billionN/A-12.08Increase in Short Interest
News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.38-4.3%$1.52 billion$35.23 million-13.86Increase in Short Interest
AlloVir logo
ALVR
AlloVir
1.4$22.18-1.9%$1.47 billionN/A0.00Increase in Short Interest
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
Replimune Group logo
REPL
Replimune Group
1.5$30.23-2.8%$1.45 billionN/A-17.08
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.08-2.6%$1.42 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.84-4.5%$1.42 billion$7.80 million-17.61
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.55-6.7%$1.34 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.78-0.4%$1.06 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.34-0.7%$1.04 billion$356.07 million7.03
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.41-5.9%$1.00 billionN/A0.00Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.00-6.8%$979.79 million$42.74 million-222.22Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$24.53-1.5%$940.63 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Passage Bio logo
PASG
Passage Bio
1.8$16.16-6.4%$925.89 millionN/A0.00Increase in Short Interest
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.77-7.2%$919.28 million$250,000.00-6.91Analyst Upgrade
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.01-0.8%$911.40 millionN/A-4.13Insider Selling
Increase in Short Interest
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.